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NF-jBSplicing, a process for mRNA maturation, is essential for correct gene expression after transcription.
However, recent studies also suggest that splicing affects transcription, but itsmechanism remains elu-
sive. We previously reported that treatment with spliceostatin A (SSA), a speciﬁc splicing inhibitor tar-
geting the splicing factor SF3b, leads to transcriptional activation of a small subset of genes. To
investigate the underlying mechanism we utilized luciferase reporters driven by the Interleukin 8 (IL-
8) and cytomegalovirus (CMV) promoters, as both recruit a similar set of transcription factors. We also
found that SSA treatment led to increased extracellular signal-regulated protein kinase (ERK) activity
and that chemical inhibitionofERKalso led todecreasedpromoter activation. Systematicdeletionstud-
ies suggested that NF-jB activation is mainly responsible for SSA-induced promoters activation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction of transcription factors we used luciferase reporter constructs ofSplicing of primary transcripts (pre-mRNA) removes non-cod-
ing intronic sequences and joins exonic sequences to make a ma-
ture mRNA that can be transported from the nucleus into the
cytoplasm and translated into protein [1]. Thus, splicing is a key
mechanism for regular gene expression and interference with
splicing will affect gene expression. Recently, FR901464 and its
methylated derivative spliceostatin A (SSA) (Fig. 1A) were reported
for the ﬁrst time to inhibit pre-mRNA splicing by binding non-
covalently to the SF3b sub-complex in the U2 snRNP [2,3]. SSA is
chemically more stable than its parent molecule FR901464, which
was originally isolated from a Pseudomonas fermentation broth.
During screening of microbial metabolites, FR901464 was found
to activate viral promoters including those of the SV40 and the
cytomegalovirus (CMV) [4,5]. Previous studies have shown that
SSA leads to transcriptional repression of about 20% of expressed
genes, while enhancing transcription of only a small subset [6].
Among the most highly upregulated genes was Interleukin-8 (IL-
8). Since IL-8 and CMV promoters are activated by a similar seteach promoter for a comparative study.
IL-8 is a well-studied CXC family chemokine that activates, and
recruits leukocytes to the site of inﬂammation [7]. Interleukin-1
(IL-1), tumor necrosis factor alpha (TNF-a) and phorbol 12-myris-
tate 13-acetate (PMA) are well known inducers of IL-8 [7,8]. These
inducers can enhance the transcriptional stimulatory activity of vir-
al promoters (SV40 and CMV) as well and are also able to activate
signaling kinases [9–12]. Previous investigations suggested that IL-
8 production is regulated by extracellular signal-regulated protein
kinase (ERK) and transcription factor NF-jB in response to TNFa,
IL-1b or PMA [13–16]. To better understand the underlying mecha-
nismwe investigated both possible upstream signaling pathways as
well as likely transcription factors responsible for IL-8 induction. The
mitogen-activated protein kinases (MAPKs) are important signaling
kinases that activate a variety of transcription factors through phos-
phorylation. Here we report that SSA treatment induces ERK activa-
tion and that SSA treatment leads to enhanced NF-jB activity.
2. Material and methods
2.1. Materials, cell lines and antibodies
A549, NIH3T3, NCL-5 and HeLa cells were maintained in DMEM
with 10% FBS and antibiotics. NCL-5 cells are a stably transfected
Fig. 1. Spliceostatin A (SSA) treatment leads to CMV and IL-8 promoter activation. Structures of parent compound FR901464 and SSA (A). SSA induced expression of the CMV
promoter in NCL-5 cells harboring a CMV-luciferase construct (B). Relative concentration of the luciferase protein by Western blot (C). Similar results were observed with the
IL-8 promoter in transiently transfected NIH3T3 cells (D, E).
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moter [17]. Parthenolide and PD98059 were purchased fromWako
Chemicals and Cell signaling technologies, respectively.
2.2. Antibodies and immunoblotting
Antibodies against anti-phospho-ERK1/2 and anti-aERK were
purchased from Cell Signaling Technology. Antibodies against
luciferase (sc-32896), SAP145 (sc-101133), NF-jB-p65 (sc-109)
and IjBa (sc-371) were purchased from Santa Cruz Biotechnology.
Antibodies against SAP130, SAP155 and b-actin were purchased
from Abcam. A mouse monoclonal anti a-Tubulin (B-5-1-2) anti-
body was from Sigma. Cells were lysed in NETN lysis buffer
(50 mM tris–Hcl pH7.5, 150 mM NaCl, 5 mM EDTA, 0.1% Nonidet
P-40), containing 1 protease inhibitor cocktail (Roche), and pro-
tein concentrations were determined by Bradford assay. Cell lysate
was dissolved in 1 SDS–PAGE sample buffer and heated to 95 C
for 5 min. 20 lg of total protein was resolved on 10% SDS–PAGE
and transferred to a polyvinylidene diﬂuoride (PVDF) membrane
(Millipore) by electroblottting. Membranes were blocked in skim
milk followed by incubation with primary and secondary antibod-
ies, and immune complexes were detected with Immobilon™Wes-
tern Chemiluminescent HRP substrate (Millipore) in a LAS-3000
image analyzer (GE Healthcare).
2.3. Immunoﬂuorescence microscopy
Cells grown on a coverslip, were treated with vehicle control or
SSA (100 ng/ml) for indicated time points followed by 15 min ﬁxa-
tion in 4% paraformaldehyde. Cells were then permeabilized in
0.2% Triton X-100 in PBS (PBT), followed by blocking in 0.1% PBT
containing 5% normal goat serum (PBTN) for 15 min. Immunosta-
tining was performed with the anti-NF-jB-p65 primary antibody(1:200 dilution), for 1–2 h followed by an Alexa Fluor 594-conju-
gated secondary antibody (Invitrogen) for 20 min. Slides were
mounted with mounting medium (Vector Laboratories), and
images were taken using a Delta Vision ﬂuorescent microscope
(SEKI Technotron Corp.).
2.4. Expression and knockdown
NIH3T3 and A549 cells were seeded at 5  104 cells per well in a
24 well multi-well plate and transfected with expression vectors
using Lipofectamine™ LTX (Invitrogen) for 48 h or FuGENE+ HD
(Roche) for 72 h. The pCR3.1-Luc vector containing the wild type
CMV promoter was kindly provided by Dr. Weber [18]. Deletion
mutants and transcription factor point mutants of IL-8 were pre-
pared as described [19]. Cells were lysed in NETN buffer after treat-
ment with compounds at the indicated time points and luciferase
activity was measured with a SpectraMax Luminometer (Molecu-
lar Devices). Small Interference RNA (siRNA) for SAP130, SAP145,
SAP155 and control non-speciﬁc siRNA sequences were from
Dharmacon, while those for NF-kB-p65 were from Nippon Gene
(Table-S1).
3. Results
3.1. Effect of spliceostatin A (SSA) on IL-8 and CMV promoters
Previous studies suggest that SSA enhances the transcription
from the SV40 viral promoter in M-8 cells [2] and the CMV pro-
moter in NCL-5 cells [5]. A recent report on microarray data of
HeLa cells treated with SSA showed signiﬁcant upregulation of
the IL-8 gene. To reproduce previous ﬁndings we began our study
with luciferase reporter assays based on the CMV and IL-8
promoters. (Fig. 1B–E). SSA-induced gene activation proceeds in a
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enhances the activity of IL-8 and CMV promoters. Acetylated SSA,
an inactive derivative of SSA as a control, showed no effect (data
not shown). Hence, increased expression appears due to splicing
inhibition and does not stem from off-target activity. To further
conﬁrm that splicing inhibition caused the observed activity, we
utilized RNA interference against subunits of the SF3b complex
(Fig. S1B). Since knockdown of spliceosomal components alone
also led to promoter activation, we can rule out an alternative
cause for SSA’s effect on transcription (S1C, D).
3.2. The ERK MAPK pathway plays a role in IL-8 and CMV promoter
up-regulation in response to SSA
It is well documented that MAP kinase signaling signiﬁcantly
up-regulates IL-8 gene expression [7]. To elucidate the role of
MAPK signaling pathways on IL-8 and CMV promoter stimulation,
we monitored kinase activation by Western blot analysis. We
found that SSA caused ERK activation in a time-dependent manner.
A signiﬁcant increase in phosphorylation was observed starting
three hours past SSA challenge (Fig. 2A). Furthermore, the activa-
tion of IL-8 and CMV promoters was sensitive to PD90859, a
MEK inhibitor (Fig. 2B–D). We found that the induction of CMV
promoter-driven transcription was inhibited upon addition of
PD98059 in a dose-dependent manner (Fig. S2). These results indi-
cate a connection between ERK activity and activation of the CMV
and IL-8 promoters.
3.3. An essential role for NF-jB in the regulation of IL-8 and CMV
promoters
The general architecture of the IL-8 promoter with its transcrip-
tion factor binding sites is well established (Fig. 3A). We utilized
promoter deletion mutants as shown to detect which region was
involved in SSA-dependent transactivation. All constructs could
be activated to similar extent except for the shortest construct,Fig. 2. Activation of the ERK signaling pathway. SSA (100 ng/ml) treatment led to increas
cells were pretreated with MEK inhibitor PD098059 (100 lM) for 1 h followed by SSA
promoter activation conﬁrmed by luciferase assay (C). Similar results were observed w
assay (D). Error bars represent standard error of mean.which only contained 50 nucleotides upstream of the transcription
start site. The next longer construct containing 98 upstream nucle-
otides showed already signiﬁcant activation upon SSA treatment.
Therefore, the key regulator most likely resides between nucleo-
tides 50 and 98, which best corresponds to both a known NF-jB
binding site as well as the binding sequence for NF-IL6 (Fig. 3B).
To identify the transcription factor responsible, we utilized vari-
ants of a construct containing 133 upstream nucleotides, with each
of the known transcription factor binding sites individually deleted
(Fig. 3C). Deletion of the NF-jB site abolished transactivation al-
most completely, while rendering the NF-IL6 binding region non-
functional had, if anything, a stimulatory effect (Fig. 3D).
3.4. SSA affects the canonical NF-jB pathway
NF-jB activation takes place following the phosphorylation of
IjBa, which results in its ubiquitination and rapid degradation
by the proteasome, allowing NF-jB to translocate to the nucleus
[14]. Otherwise the IjB–NF-jB complex will remain in the cyto-
plasm [20]. Using immuno-histochemistry, we observed the cellu-
lar localization of the NF-jB subunit p65 under SSA treatment. As
shown in Fig. 4A, the amount of nuclear p65 increased after SSA
application. Meanwhile, IjBa was decreased in a time-dependent
manner (Fig. 4B). Therefore, it appears most likely that lack of suf-
ﬁcient IjBa leads to persistent activation of the NF-jB pathway.
Furthermore, we found that parthenolide, a NF-jB pathway inhib-
itor that speciﬁcally inhibits the phosphorylation of IjBa by up-
stream kinases [21], also decreased the stimulatory effect of SSA
upon CMV and IL-8 promoters (Fig. 4C and D).
As further conﬁrmation we knocked down the p65 subunit to
see if NF-jB is required for transcriptional activation upon SSA
treatment (Fig. S3). Knockdown of p65 clearly inhibited the SSA-in-
duced IL-8 gene transcription activity. Furthermore, cells treated
with parthenolide showed reduced levels of IjBa, however the
NF-jB inhibitor did appear to rescue the remaining protein from
degradation upon SSA treatment (Fig. S4).ed ERK activation over time in NCL-5 cells as determined by Western blot (A). NCL-5
(100 ng/ml) for 12 h. PD reduced SSA-induced ERK phosphorylation (B) and CMV
ith the IL-8 promoter in transiently transfected A549 cells, conﬁrmed by luciferase
Fig. 3. Identiﬁcation of the transcription factor responsive to SSA treatment. Constructs containing various lengths of the IL-8 promoter linked to a luciferase reporter were
used (A). NIH3T3 cells were transiently transfected with 50 ﬂanking deletion mutants of the IL-8 gene for 48 h, followed by incubation with and without SSA (100 ng/ml) for
12 h. Activity of each mutant was measured by luciferase assay (B). Diagram outlining deletion mutants of the IL-8 core promoter, lacking individual transcription factor
binding sites (C). NIH3T3 cells were transiently transfected with wild type, IL-8 (-133)-Luc, mAP-1, mNF-IL6 and mNF-kB deletion mutants. Luciferase activity 48 h post
transfection was measured upon 12 h SSA (100 ng/ml) treatment. Constructs without the NF-jB binding site become unresponsive to SSA-induced promoter activation.
Fig. 4. SSA treatment leads to NF-jB activation. p65 translocated to the nucleus upon SSA treatment. NIH3T3 cells were treated for 12 h with either methanol (upper panel)
or SSA (100 ng/ml) (lower panel), nuclear localization of the p65 subunit was determined by immunostaining (A). IjBa degradation was observed by Western blot at different
time intervals (B). Levels of CMV (C) and IL-8 (D) promoter activation by SSA (100 ng/ml) for 12 h were determined by luciferase reporter assay in transiently transfected A549
cells in the presence or absence of 40 lM parthenolide.
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Here we show that part of the transcriptional upregulation
observed during splicing inhibition, stems from activation of the
NF-jB signaling pathway. The promoter region of IL-8 containsputative binding sites for NF-jB, NF-IL6 and AP-1 [22]. Site direc-
ted mutagenesis of each binding site showed that SSA mediated
transactivation mainly depends on NF-jB. This was consistent
with results obtained via small interfering RNA (siRNA) silencing
of the p65 subunit of NF-jB or use of the NF-jB-speciﬁc inhibitor
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tion of a small subset of genes during splicing inhibition depends
on ERK activity and on NF-jB.
As the amount of the key inhibitory factor, IjBa decreases with
SSA treatment, more NF-jB can translocate to the nucleus. Indeed,
other NF-jB target genes, such as superoxide dismutase (SOD2),
experience upregulation under SSA treatment [6]. Furthermore,
we found evidence for an involvement of the ERK kinase pathways
in gene activation during splicing inhibition. It would appear plau-
sible that ERK phosphorylates and activates the upstream kinase of
the NF-jB pathway IKK [23]. Our data are consistent with a con-
nection between ERK signaling and NF-jB activity [24].
In summary, we have documented that chemical inhibition
of splicing activated ERK signaling and the transcription factor
NF-jB. This provides the ﬁrst explanation how inhibition of
pre-mRNA splicing can have an activating effect on a speciﬁc sub-
set of genes. Since splicing inhibitors have documented antitumor
activity, with some even entering clinical trials, NF-jB activity can
be critical, as the pathway generally aids in cell proliferation and
survival. Further studies will show whether this induced NF-jB
activity aids or counteracts antitumor efﬁcacy.
Acknowledgments
We thank Dr. Georg F. Weber for kindly providing pCR3.1-Luc.
This work was supported in part by the Grants-in-Aid for Scientiﬁc
Research (S) of JSPS KAKENHI Grant No. 21228003 and the CREST
Research Project, the Japan Science and Technology Corporation.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2014.02.
018.
References
[1] Wahl, M.C., Will, C.L. and Lührmann, R. (2009) The spliceosome: design
principles of a dynamic RNP machine. Cell 136 (4), 701–718.
[2] Nakajima, H. et al. (1996) New antitumor substances, FR901463, FR901464
and FR901465. II. Activities against experimental tumors in mice and
mechanism of action. J. Antibiot. (Tokyo) 49 (12), 1204–1211.
[3] Kaida, D. et al. (2007) Spliceostatin A targets SF3b and inhibits both splicing
and nuclear retention of pre-mRNA. Nat. Chem. Biol. 3 (9), 576–583.
[4] Nakajima, H. et al. (1996) New antitumor substances, FR901463, FR901464
and FR901465. I. Taxonomy, fermentation, isolation, physico-chemical
properties and biological activities. J. Antibiot. (Tokyo) 49 (12), 1196–1203.[5] Motoyoshi, H. et al. (2004) Structure-activity relationship for FR901464: a
versatile method for the conversion and preparation of biologically active
biotinylated probes. Biosci. Biotechnol. Biochem. 68 (10), 2178–2182.
[6] Furumai, R. et al. (2010) Spliceostatin A blocks angiogenesis by inhibiting
global gene expression including VEGF. Cancer Sci. 101 (11), 2483–
2489.
[7] Waugh, D.J. and Wilson, C. (2008) The interleukin-8 pathway in cancer. Clin.
Cancer Res. 14 (21), 6735–6741.
[8] Wilson, K.S. and Noller, H.F. (1998) Molecular movement inside the
translational engine. Cell 92 (3), 337–349.
[9] Imbra, R.J. and Karin, M. (1986) Phorbol ester induces the transcriptional
stimulatory activity of the SV40 enhancer. Nature 323 (6088), 555–
558.
[10] Plaetinck, G. et al. (1989) Interleukin 1 and tumor necrosis factor enhance
transcription from the SV40 early promoter in a T cell line. Eur. J. Immunol. 19
(5), 897–904.
[11] Shifera, A.S. and Hardin, J.A. (2009) PMA induces expression from the herpes
simplex virus thymidine kinase promoter via the activation of JNK and ERK in
the presence of adenoviral E1A proteins. Arch. Biochem. Biophys. 490 (2),
145–157.
[12] Stein, J. et al. (1993) Tumour necrosis factor alpha stimulates the activity of
the human cytomegalovirus major immediate early enhancer/promoter in
immature monocytic cells. J. Gen. Virol. 74 (Pt 11), 2333–2338.
[13] Alcorn, M.J. et al. (2001) Adenovirus type 7 induces interleukin-8 production
via activation of extracellular regulated kinase 1/2. J. Virol. 75 (14), 6450–
6459.
[14] Hoffmann, E. et al. (2002) Multiple control of interleukin-8 gene expression. J.
Leukoc. Biol. 72 (5), 847–855.
[15] Saadane, A. et al. (2007) Parthenolide inhibits IkappaB kinase, NF-kappaB
activation, and inﬂammatory response in cystic ﬁbrosis cells and mice. Am. J.
Respir. Cell Mol. Biol. 36 (6), 728–736.
[16] Saadane, A. et al. (2011) Parthenolide inhibits ERK and AP-1 which are
dysregulated and contribute to excessive IL-8 expression and secretion in
cystic ﬁbrosis cells. J. Inﬂamm. (Lond.) 8, 26.
[17] Kim, Y.B. et al. (1999) Oxamﬂatin is a novel antitumor compound that inhibits
mammalian histone deacetylase. Oncogene 18 (15), 2461–2470.
[18] He, B. and Weber, G.F. (2004) Synergistic activation of the CMV promoter by
NF-kappaB P50 and PKG. Biochem. Biophys. Res. Commun. 321 (1), 13–
20.
[19] Mori, N. et al. (1998) Human T-cell leukemia virus type I Tax transactivates
human interleukin 8 gene through acting concurrently on AP-1 and nuclear
factor-kappaB-like sites. Cancer Res. 58 (17), 3993–4000.
[20] Traenckner, E.B., Wilk, S. and Baeuerle, P.A. (1994) A proteasome inhibitor
prevents activation of NF-kappa B and stabilizes a newly phosphorylated form
of I kappa B-alpha that is still bound to NF-kappa B. EMBO J. 13 (22), 5433–
5441.
[21] Hehner, S.P. et al. (1999) The antiinﬂammatory sesquiterpene lactone
parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex.
J. Immunol. 163 (10), 5617–5623.
[22] Elliott, C.L. et al. (2001) Nuclear factor-kappa B is essential for up-regulation of
interleukin-8 expression in human amnion and cervical epithelial cells. Mol.
Hum. Reprod. 7 (8), 787–790.
[23] Zhao, Q. and Lee, F.S. (1999) Mitogen-activated protein kinase/ERK kinase
kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha
and IkappaB kinase-beta. J. Biol. Chem. 274 (13), 8355–8358.
[24] Jiang, B. et al. (2004) Temporal control of NF-kappaB activation by ERK
differentially regulates interleukin-1beta-induced gene expression. J. Biol.
Chem. 279 (2), 1323–1329.
